# OnCo record glenmark (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/glenmark/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "glenmark" ;
  schema:name "Glenmark Pharmaceuticals (Ichnos Glenmark Innovation)"@en ;
  schema:description "The Indian company whose trispecific antibody ISB 2001 for multiple myeloma was licensed to AbbVie in 2025 for 700 million dollars upfront, the largest deal for an Indian-discovered cancer drug."@en ;
  schema:url <https://onco.cc/companies/glenmark/>, <https://www.glenmarkpharma.com> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.glenmarkpharma.com> ;
  schema:addressCountry "IN" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/>, <https://onco.cc/fronts/adcs/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/bcma/>, <https://onco.cc/targets/cd38/>, <https://onco.cc/targets/her2/> ;
  onco:drugs <https://onco.cc/drugs/isb-2001/>, <https://onco.cc/drugs/trastuzumab-rezetecan/> ;
  onco:companies <https://onco.cc/companies/abbvie/>, <https://onco.cc/companies/hengrui/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-translational-valley/> .